HK1201466A1 - 用於治療糖尿病的β-內醯胺化合物 - Google Patents

用於治療糖尿病的β-內醯胺化合物

Info

Publication number
HK1201466A1
HK1201466A1 HK15102059.7A HK15102059A HK1201466A1 HK 1201466 A1 HK1201466 A1 HK 1201466A1 HK 15102059 A HK15102059 A HK 15102059A HK 1201466 A1 HK1201466 A1 HK 1201466A1
Authority
HK
Hong Kong
Prior art keywords
treating diabetes
lactam compounds
beta lactam
beta
compounds
Prior art date
Application number
HK15102059.7A
Other languages
English (en)
Inventor
艾潤‧
‧科恩
菲利克斯‧莫爾
Original Assignee
Stem Cell Medicine Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stem Cell Medicine Ltd filed Critical Stem Cell Medicine Ltd
Publication of HK1201466A1 publication Critical patent/HK1201466A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • A61K38/385Serum albumin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/462Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/46433Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
HK15102059.7A 2011-09-21 2015-03-02 用於治療糖尿病的β-內醯胺化合物 HK1201466A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161537105P 2011-09-21 2011-09-21
PCT/IL2012/050378 WO2013042121A1 (en) 2011-09-21 2012-09-20 Beta-lactam compounds for treating diabetes

Publications (1)

Publication Number Publication Date
HK1201466A1 true HK1201466A1 (zh) 2015-09-04

Family

ID=47913973

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102059.7A HK1201466A1 (zh) 2011-09-21 2015-03-02 用於治療糖尿病的β-內醯胺化合物

Country Status (8)

Country Link
US (1) US9474744B2 (zh)
EP (1) EP2758054B1 (zh)
CN (1) CN104023721A (zh)
AU (1) AU2012311050A1 (zh)
BR (1) BR112014005864A2 (zh)
CA (1) CA2850558A1 (zh)
HK (1) HK1201466A1 (zh)
WO (1) WO2013042121A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020210983B2 (en) * 2019-01-23 2024-05-16 Glycolysis Biomed Co., Ltd Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorder
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
WO2021252917A2 (en) 2020-06-11 2021-12-16 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA94128B (en) 1993-02-01 1994-08-19 Univ New York State Res Found Process for the preparation of taxane derivatives and betalactam intermediates therefor
EP0869943A1 (en) 1995-12-08 1998-10-14 Smithkline Beecham Plc Monocyclic beta-lactame derivatives for treatment of atherosclerosis
US6130087A (en) 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
US6255467B1 (en) 1997-11-06 2001-07-03 Pathobiotek Diagnostics Inc. Human blood bacterium
LV12403B (lv) 1998-06-10 2000-02-20 Latvijas Organiskās Sintēzes Institūts Citotoksiskie penicilānskābes atvasinājumi
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
NZ517663A (en) 1999-08-16 2006-02-24 Revaax Pharmaceuticals Llc Neurotherapeutic clavulanate composition and method
US7638326B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
AU2003202942A1 (en) 2002-01-17 2003-09-02 R.E.D. Laboratories, N.V./S.A. Methods of treatment of chronic immune disease
US7026472B2 (en) 2002-05-06 2006-04-11 University Of South Florida Methods for preventing and treating cancer using N-thiolated β-lactam compounds and analogs thereof
WO2005121148A2 (en) 2004-06-08 2005-12-22 Nereus Pharmaceuticals, Inc. Anti-bacterial and anti-cancer spiro beta-lactone/gamma-lactams
ATE490976T1 (de) 2004-10-30 2010-12-15 Univ Pais Vasco B-lactam-rgd-cyclopeptide mit gamma-(g-)wendungen
AU2006339311A1 (en) 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
KR100697312B1 (ko) 2005-08-31 2007-03-20 한국생명공학연구원 세프트리악손을 포함하는 stat3 활성 저해 활성을가지는 조성물
US8722343B2 (en) * 2008-11-21 2014-05-13 Carla Perego Methods and compositions for the diagnosis and treatment of diabetes
CN101524517A (zh) 2009-04-28 2009-09-09 李红彬 一种治疗上呼吸道感染的中西复合药物
WO2011047153A1 (en) * 2009-10-15 2011-04-21 President And Fellows Of Harvard College Methods for modulating autoimmunity
WO2012103456A2 (en) 2011-01-27 2012-08-02 Board Of Regents, The University Of Texas System Polycyclic beta lactam derivatives for the treatment of cancer

Also Published As

Publication number Publication date
BR112014005864A2 (pt) 2017-03-28
CA2850558A1 (en) 2013-03-28
CN104023721A (zh) 2014-09-03
US20140234282A1 (en) 2014-08-21
EP2758054A1 (en) 2014-07-30
EP2758054B1 (en) 2017-04-12
US9474744B2 (en) 2016-10-25
EP2758054A4 (en) 2015-03-04
WO2013042121A1 (en) 2013-03-28
AU2012311050A1 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
IL286152A (en) Modified imidazopyridinyl-aminopyridine compounds
HK1202059A1 (zh) 用於治療脊髓性肌萎縮症的化合物
ZA201502811B (en) Apparatus for motion compensation
HK1200484A1 (zh) 多聚寡核苷酸化合物
EP2902020A4 (en) COMPOSITION FOR REDUCING NEW DIABETES APPARITIONS
IL220889A (en) Anti-dll4 antibody to treat diabetes
EP2709609A4 (en) HETEROCYCLIC COMPOUNDS
IL230594A0 (en) Process for the preparation of nitrogen-substituted 1h-pyrazole-5-carbonyl chloride compounds
IL253421B (en) Compounds for the treatment of fibrosis (Leifat)
EP2590643A4 (en) MEDICINAL PRODUCT MADE FROM SEVERAL INGREDIENTS FOR THE TREATMENT OF DIABETES
SG11201405296QA (en) Method for purifying acetonitrile
EP2774917A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES
HK1210969A1 (zh) 用於疾病治療的取代的雜環化合物
SG11201501216XA (en) Method for purifying acetonitrile
PL3202769T3 (pl) Sposoby oczyszczania związków fosfaplatyny
HK1201466A1 (zh) 用於治療糖尿病的β-內醯胺化合物
HK1190706A1 (zh) 作為用於治療糖尿病的 抑制劑的仲-羥基環己基衍生物
GB201117172D0 (en) Diabetes
GB201105659D0 (en) Compounds
EP2691104A4 (en) USE OF EZATIOSTAT IN THE TREATMENT OF MULTIPLE MYELOMA
EP2683746A4 (en) OLIGOSACCHARIDE COMPOUNDS
PL2578759T3 (pl) Mechanizm ryglujący dla odpływu
EP2563353A4 (en) COMPOUNDS FOR ANTIFUNGAL TREATMENT
HK1214960A1 (zh) 用於純化肝素- -硫酸的方法
IL231480A0 (en) Beta-lactam compounds for the treatment of diabetes